Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: A retrospective study

Vito Di Lernia, Cinzia Ricci, Aimilios Lallas, Elena Ficarelli

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Anti-tumor necrosis factor (TNF)-α therapies represent a significant innovation in therapy for psoriasis. However, a significant number of psoriasis patients do not respond well to TNF blockers or show an insufficient control of disease activity on a long-term basis. Objective/aim: The aim of this study was to recognize specific clinical factors that could be associated with a non-response to any available TNF blockers in patients with moderate-to-severe plaque psoriasis. Materials and methods: The authors reviewed the medical records of all patients who had started etanercept, infliximab, adalimumab and had achieved a minimum of 24 months follow-up. The authors identified subjects who were not responsive to all available anti-TNF agents, whatever the chronology of their use. Results: A total of 110 patients were retrospectively examined. Thirteen patients were identified as "non-responders" to all available TNF-α blockers. Current smoking at the start of anti-TNF therapy was associated with non-response to TNF blockers. The group of "non-responders" presented a high mean body mass index and a high baseline PASI score with respect to the group of responders. Conclusions: The data showed that the majority of non-responder patients were smokers, overweight or obese and had a high baseline PASI score. Concomitant arthritis was not significantly associated with non-response.

Original languageEnglish
Pages (from-to)73-74
Number of pages2
JournalJournal of Dermatological Treatment
Volume25
Issue number1
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Retrospective Studies
Tumor Necrosis Factor-alpha
Psoriasis
Chronology
Arthritis
Medical Records
Body Mass Index
Therapeutics
Smoking

Keywords

  • Adalimumab
  • Anti-TNF
  • Etanercept
  • Infliximab
  • Non-responders
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers : A retrospective study. / Di Lernia, Vito; Ricci, Cinzia; Lallas, Aimilios; Ficarelli, Elena.

In: Journal of Dermatological Treatment, Vol. 25, No. 1, 02.2014, p. 73-74.

Research output: Contribution to journalArticle

@article{76103ae92ec948258ee509f9d508e3cc,
title = "Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: A retrospective study",
abstract = "Background: Anti-tumor necrosis factor (TNF)-α therapies represent a significant innovation in therapy for psoriasis. However, a significant number of psoriasis patients do not respond well to TNF blockers or show an insufficient control of disease activity on a long-term basis. Objective/aim: The aim of this study was to recognize specific clinical factors that could be associated with a non-response to any available TNF blockers in patients with moderate-to-severe plaque psoriasis. Materials and methods: The authors reviewed the medical records of all patients who had started etanercept, infliximab, adalimumab and had achieved a minimum of 24 months follow-up. The authors identified subjects who were not responsive to all available anti-TNF agents, whatever the chronology of their use. Results: A total of 110 patients were retrospectively examined. Thirteen patients were identified as {"}non-responders{"} to all available TNF-α blockers. Current smoking at the start of anti-TNF therapy was associated with non-response to TNF blockers. The group of {"}non-responders{"} presented a high mean body mass index and a high baseline PASI score with respect to the group of responders. Conclusions: The data showed that the majority of non-responder patients were smokers, overweight or obese and had a high baseline PASI score. Concomitant arthritis was not significantly associated with non-response.",
keywords = "Adalimumab, Anti-TNF, Etanercept, Infliximab, Non-responders, Psoriasis",
author = "{Di Lernia}, Vito and Cinzia Ricci and Aimilios Lallas and Elena Ficarelli",
year = "2014",
month = "2",
doi = "10.3109/09546634.2013.800184",
language = "English",
volume = "25",
pages = "73--74",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers

T2 - A retrospective study

AU - Di Lernia, Vito

AU - Ricci, Cinzia

AU - Lallas, Aimilios

AU - Ficarelli, Elena

PY - 2014/2

Y1 - 2014/2

N2 - Background: Anti-tumor necrosis factor (TNF)-α therapies represent a significant innovation in therapy for psoriasis. However, a significant number of psoriasis patients do not respond well to TNF blockers or show an insufficient control of disease activity on a long-term basis. Objective/aim: The aim of this study was to recognize specific clinical factors that could be associated with a non-response to any available TNF blockers in patients with moderate-to-severe plaque psoriasis. Materials and methods: The authors reviewed the medical records of all patients who had started etanercept, infliximab, adalimumab and had achieved a minimum of 24 months follow-up. The authors identified subjects who were not responsive to all available anti-TNF agents, whatever the chronology of their use. Results: A total of 110 patients were retrospectively examined. Thirteen patients were identified as "non-responders" to all available TNF-α blockers. Current smoking at the start of anti-TNF therapy was associated with non-response to TNF blockers. The group of "non-responders" presented a high mean body mass index and a high baseline PASI score with respect to the group of responders. Conclusions: The data showed that the majority of non-responder patients were smokers, overweight or obese and had a high baseline PASI score. Concomitant arthritis was not significantly associated with non-response.

AB - Background: Anti-tumor necrosis factor (TNF)-α therapies represent a significant innovation in therapy for psoriasis. However, a significant number of psoriasis patients do not respond well to TNF blockers or show an insufficient control of disease activity on a long-term basis. Objective/aim: The aim of this study was to recognize specific clinical factors that could be associated with a non-response to any available TNF blockers in patients with moderate-to-severe plaque psoriasis. Materials and methods: The authors reviewed the medical records of all patients who had started etanercept, infliximab, adalimumab and had achieved a minimum of 24 months follow-up. The authors identified subjects who were not responsive to all available anti-TNF agents, whatever the chronology of their use. Results: A total of 110 patients were retrospectively examined. Thirteen patients were identified as "non-responders" to all available TNF-α blockers. Current smoking at the start of anti-TNF therapy was associated with non-response to TNF blockers. The group of "non-responders" presented a high mean body mass index and a high baseline PASI score with respect to the group of responders. Conclusions: The data showed that the majority of non-responder patients were smokers, overweight or obese and had a high baseline PASI score. Concomitant arthritis was not significantly associated with non-response.

KW - Adalimumab

KW - Anti-TNF

KW - Etanercept

KW - Infliximab

KW - Non-responders

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=84890492966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890492966&partnerID=8YFLogxK

U2 - 10.3109/09546634.2013.800184

DO - 10.3109/09546634.2013.800184

M3 - Article

C2 - 23621374

AN - SCOPUS:84890492966

VL - 25

SP - 73

EP - 74

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 1

ER -